Effect of Austrian COVID-19 lockdowns on acute myocardial infarction frequency and long-term mortality: a multicentre observational study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
08 02 2023
Historique:
entrez: 8 2 2023
pubmed: 9 2 2023
medline: 11 2 2023
Statut: epublish

Résumé

The aim of this study was to find out if the decrease in acute myocardial infarction (AMI) admissions during the first COVID-19 lockdowns (LD), which was described by previous studies, occurred equally in all LD periods (LD1, LD2, LD2021), which had identical restrictions. Further, we wanted to analyse if the decrease of AMI admission had any association with the 1-year mortality rate. This study is a prospective observational study of two centres that are participating in the Vienna ST-elevation myocardial infarction network. A total of 1732 patients who presented with AMI according to the 4th universal definition of myocardial infarction in 2019, 2020 and the LD period of 2021 were included in our study. Patients with myocardial infarction with non-obstructive coronary arteries were excluded from our study. The primary outcome of this study was the frequency of AMI during the LD periods and the all-cause and cardiac-cause 1-year mortality rate of 2019 (pre-COVID-19) and 2020. Out of 1732 patients, 70% (n=1205) were male and median age was 64 years. There was a decrease in AMI admissions of 55% in LD1, 28% in LD2 and 17% in LD2021 compared with 2019.There were no differences in all-cause 1-year mortality between the year 2019 (11%; n=110) and 2020 (11%; n=79; p=0.92) or death by cardiac causes [10% (n=97) 2019 vs 10% (n=71) 2020; p=0.983]. All LDs showed a decrease in AMI admissions, though not to the same extent, even though the regulatory measures were equal. Admission in an LD period was not associated with cardiac or all-cause 1-year mortality rate in AMI patients in our study.

Identifiants

pubmed: 36754558
pii: bmjopen-2022-065308
doi: 10.1136/bmjopen-2022-065308
pmc: PMC9922876
doi:

Types de publication

Observational Study Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e065308

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Clin Res Cardiol. 2020 Dec;109(12):1585-1587
pubmed: 32651656
Sci Total Environ. 2020 Nov 1;741:140353
pubmed: 32593894
N Engl J Med. 2020 Aug 13;383(7):691-693
pubmed: 32427432
Curr Probl Cardiol. 2021 Mar;46(3):100656
pubmed: 32839042
Acta Cardiol. 2021 Oct;76(8):863-869
pubmed: 32727305
Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):18984-18990
pubmed: 32723816
J Am Coll Cardiol. 2020 Jun 9;75(22):2871-2872
pubmed: 32283124
Rev Esp Cardiol. 2020 Dec;73(12):994-1002
pubmed: 33071427
Eur Heart J. 2020 Jun 7;41(22):2083-2088
pubmed: 32412631
Eur Heart J. 2017 Feb 21;38(8):557-564
pubmed: 27460891
Eur Heart J Qual Care Clin Outcomes. 2021 May 3;7(3):238-246
pubmed: 32730620
J Am Coll Cardiol. 2020 Nov 17;76(20):2321-2330
pubmed: 33183506
Lancet Public Health. 2020 Oct;5(10):e536-e542
pubmed: 32950075
CJC Open. 2020 Dec 15;:
pubmed: 33521615
Int J Cardiol. 2010 Oct 29;144(3):423-5
pubmed: 19345426
Can J Cardiol. 2020 Jul;36(7):1161.e7-1161.e8
pubmed: 32437729
Ann Cardiol Angeiol (Paris). 2020 Dec;69(6):355-359
pubmed: 33069381
Circ J. 2019 Apr 25;83(5):1072-1079
pubmed: 30842356
Eur Heart J. 2020 May 14;41(19):1852-1853
pubmed: 32297932
J Am Coll Cardiol. 2020 Sep 15;76(11):1318-1324
pubmed: 32828614
Heart. 2020 Dec 17;:
pubmed: 33334863
Eur Heart J. 2019 Jan 14;40(3):237-269
pubmed: 30165617
J Thromb Thrombolysis. 2022 Feb;53(2):335-345
pubmed: 34448103
Am Heart J. 2020 Aug;226:45-48
pubmed: 32497914
Build Cities. 2021;2(1):759-778
pubmed: 34704039
Am Heart J. 2020 Aug;226:147-151
pubmed: 32569892
Circ Cardiovasc Interv. 2020 Nov;13(11):e009654
pubmed: 33138626
Circulation. 1994 Jul;90(1):87-93
pubmed: 8026056
Lancet Reg Health West Pac. 2020 Dec;5:100056
pubmed: 34173604
Lancet. 2020 Aug 8;396(10248):381-389
pubmed: 32679111
Chronobiol Int. 2005;22(1):107-20
pubmed: 15865325

Auteurs

Roya Anahita Mousavi (RA)

Karl Landsteiner Institute for Cardiovascular and Critical Care Research, Vienna, Austria.

Dominik Roth (D)

Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria.

Christian Wallmüller (C)

Karl Landsteiner Institute for Cardiovascular and Critical Care Research, Vienna, Austria.
Department of Cardiology, Clinic Floridsdorf, Vienna, Austria.

Gernot Pichler (G)

Karl Landsteiner Institute for Cardiovascular and Critical Care Research, Vienna, Austria.
Department of Cardiology, Clinic Floridsdorf, Vienna, Austria.

Peter Stratil (P)

Karl Landsteiner Institute for Cardiovascular and Critical Care Research, Vienna, Austria.
Department of Cardiology, Clinic Floridsdorf, Vienna, Austria.

Wolfgang Schreiber (W)

Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria.

Georg Delle-Karth (G)

Karl Landsteiner Institute for Cardiovascular and Critical Care Research, Vienna, Austria.
Department of Cardiology, Clinic Floridsdorf, Vienna, Austria.

Andreas Schober (A)

Karl Landsteiner Institute for Cardiovascular and Critical Care Research, Vienna, Austria andreas.schober@gesundheitsverbund.at.
Department of Cardiology, Clinic Floridsdorf, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH